PIK3CA and breast carcinoma: The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian Target Of Rapamycin (mTOR) pathway is commonly deregulated in breast cancer and consequently, there is intense interest in the clinical development of agents that target this pathway [1].